Gilead Sciences

This study tested whether a new once-weekly oral pill (GS-1720 plus GS-4182) could control HIV-1 as well as the daily standard-of-care Biktarvy. It enrolled 73 adults newly diagnosed with HIV who had never taken HIV medication. The study was terminated early, so results are limit…

This study tested an experimental drug called GS-5718 for people with cutaneous lupus erythematosus (CLE), a condition where the immune system attacks the skin. The trial aimed to see if the drug could reduce skin disease activity and was safe. Only 20 participants were enrolled,…

This study tested a new drug called magrolimab combined with other cancer treatments for people with head and neck squamous cell carcinoma that had spread or come back. The goal was to see if the combination was safe and effective. The study was terminated early, so results are l…

This study tested a new experimental HIV medicine, GS-1219, in people living with HIV-1. The goal was to see if it was safe and could lower the amount of virus in the blood. Only 4 people took part before the study was stopped early. This was a very early (Phase 1) study, so it i…

This study tested a drug called magrolimab combined with chemotherapy for people with advanced triple-negative breast cancer that cannot be removed by surgery. The goal was to see if the combination was safe and worked better than chemotherapy alone. The trial was stopped early, …